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ABSTRACT
CONTEXT AND OBJECTIVE: Metabolic syndrome consists of a set of factors that imply increased risk of 
cardiovascular diseases. The objective here was to evaluate the association between sex hormone-binding 
globulin (SHBG), sex hormones and metabolic syndrome among men. 
DESIGN AND SETTING: Retrospective analysis on data from the study “Endogenous oestradiol but not 
testosterone is related to coronary artery disease in men”, conducted in a hospital in São Paulo. 
METHODS: Men (aged 40-70) who underwent coronary angiography were selected. The age, weight, 
height, waist circumference, body mass index and prevalence of dyslipidemia, hypertension and diabe-
tes of each patient were registered. Metabolic syndrome was defined in accordance with the criteria of 
the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation 
and Treatment of High Blood Cholesterol in Adults (NCEP-ATPIII). Serum samples were collected to assess 
the levels of glucose, total cholesterol, HDL-cholesterol (high density lipoprotein), triglycerides, albumin, 
SHBG, estradiol and total testosterone (TT). The levels of LDL-cholesterol (low density lipoprotein) were 
calculated using Friedewald’s formula and free testosterone (FT) and bioavailable testosterone (BT) using 
Vermeulen’s formula. 
RESULTS: 141 patients were enrolled in the study. The prevalence of metabolic syndrome was significantly 
higher in the first SHBG tercile than in the second and third terciles. A statistically significant positive as-
sociation between the SHBG and TT values was observed, but no such association was seen between 
SHBG, BT and FT. 
CONCLUSION: Low serum levels of SHBG are associated with higher prevalence of metabolic syndrome 
among male patients, but further studies are required to confirm this association. 
RESUMO
CONTEXTO E OBJETIVO: A síndrome metabólica (SM) consiste em um conjunto de fatores que implicam 
risco elevado para doenças cardiovasculares. O objetivo foi avaliar a associação entre a globulina ligadora 
de esteroides sexuais (SHBG), hormônios sexuais e a SM em homens.  
TIPO DE ESTUDO E LOCAL: Análise retrospectiva de dados do estudo “Estradiol mas não testosterona 
se correlaciona com doença arterial coronariana em homens”, conduzido em um hospital em São Paulo.
MÉTODOS: Foram selecionados pacientes do sexo masculino com idade entre 40 e 70 anos, submetidos 
a angiografia coronária. A idade, a prevalência de dislipidemia, hipertensão e diabetes, o peso, a altura, 
cintura e o índice de massa corpórea de cada paciente foram coletados. A definição de SM seguiu os 
critérios do NCEP-ATPIII. Amostras séricas foram coletadas para análises da glicose, colesterol total, coles-
terol-HDL (high density lipoprotein), triglicerídeos, albumina, SHBG, estradiol e testosterona total (TT). O 
colesterol-LDL (low density lipoprotein) foi calculado pela fórmula de Friedewald e as testosteronas livre (TL) 
e biodisponível (TB) pela fórmula de Vermeulen.
RESULTADOS: Entraram no estudo 141 pacientes. A prevalência de SM foi significativamente maior no pri-
meiro tercil de SHBG em comparação ao segundo e terceiro tercis. Foi verificada uma associação positiva 
e significativa ente os valores de SHBG e TT, porém essa associação não foi verificada entre SHBG e TB e TL.
CONCLUSÃO: Baixos níveis séricos de SHBG estiveram associados com alta prevalência da SM em pacien-
tes do sexo masculino. Faz-se necessário que estudos avaliem essa associação.
IMD, PhD. Endocrinologist, Universidade Federal 
do Ceará (UFC), Barbalha, Ceará, Brazil.
IIMD. Cardiologist and Hemodynamicist, 
Universidade Federal do Ceará (UFC), Barbalha, 
Ceará, Brazil.
IIIMSc. Pharmacist, Universidade Federal de São 
Paulo (Unifesp), São Paulo, Brazil.
IVMD, PhD. Cardiologist and Hemodynamicist, 
Instituto Dante Pazzanese de Cardiologia, São 
Paulo, Brazil.
VMD, PhD. Endocrinologist, Universidade Federal 
de São Paulo, (Unifesp), São Paulo, Brazil.
KEY WORDS:
Sex hormone-binding globulin. 
Metabolic syndrome X. 
Men. 
Coronary artery disease. 
Coronary angiography.
PALAVRAS-CHAVE:
Globulina de ligação a hormônio sexual. 
Síndrome X metabólica. 
Homens. 
Doença da artéria coronariana. 
Angiografia coronária.
ORIGINAL ARTICLE | Callou de Sá EQ, Sá FCF, Oliveira KC, Feres F, Verreschi ITN
112     Sao Paulo Med J. 2014; 132(2):111-5
INTRODUCTION 
Metabolic syndrome consists of a set of factors that confer 
increased risk of cardiovascular diseases, including obesity (espe-
cially abdominal obesity), insulin resistance (regardless of the 
presence of diabetes mellitus), dyslipidemia (increased triglycer-
ide levels and reduced HDL cholesterol levels) and systemic arte-
rial hypertension (SAH). The primary abnormality relating to 
metabolic syndrome appears to be insulin resistance in periph-
eral tissues.1
Sex hormone-binding protein (SHBG), which is produced 
by the liver, binds to testosterone with high affinity and to estra-
diol (E2) with lower affinity. Insulin is an important regulator of 
SHBG production in the liver. In vitro studies have shown that 
physiological concentrations of insulin inhibit SHBG produc-
tion in cultured hepatoma cells.2 Pasquali et al.3 showed that 
inhibition of insulin secretion by means of diazoxide induces 
an increase in SHBG levels, both in obese men and in men with 
normal body weights. In addition, men who present low SHBG 
concentrations are at increased risk of developing metabolic syn-
drome.4 The prevalence of concomitant dyslipidemia, hyperten-
sion and diabetes suggests that insulin resistance may be a deter-
minant of SHBG levels. 
OBJECTIVE
This study assessed the association between SHBG, sex hor-
mones and prevalence of metabolic syndrome.
METHODS 
Study design 
This study was conducted by performing a retrospective analysis 
on the data from a previous study, “Endogenous oestradiol, but 
not testosterone, is related to coronary artery disease in men”.5
Study population 
We selected male patients aged 40-70 years who were admitted to 
hospital in order to undergo coronary angiography for investiga-
tion and/or staging of ischemic heart disease, at Hospital Dante 
Pazzanese de Cardiologia. Patients who were smokers, were 
using anti-androgenic drugs (such as ketoconazole, cimetidine, 
spironolactone, androcur or finasteride) or had a previous his-
tory of myocardial infarction, stroke and/or major surgery within 
the past six months were excluded from the study. In addition, 
individuals with a body mass index (BMI, defined as weight in kg 
divided by the square of height in meters) ≥ 40 kg/m2 or serum 
creatinine levels > 2.0 mg/dl, and patients who showed evidence 
of major liver disease during clinical examinations were also 
excluded from the study.
After verifying the study inclusion criteria, the patients were 
divided into three groups based on SHBG terciles.
Informed consent was obtained from all subjects, and the 
project had previously been approved by the Ethics Committees 
of the two participating institutions.
Assessments
Data on age, prevalence of components of metabolic syndrome 
(obesity, dyslipidemia, SAH and diabetes), current medications, 
weight, height and waist circumference measurements and BMI 
were gathered in relation to each patient through standard ques-
tionnaires immediately after the individual had been given expla-
nations about the study and had consented to participation in it. 
Metabolic syndrome was defined in accordance with the criteria 
recommended by the Third Report of the National Cholesterol 
Education Program Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults (NCEP-ATPIII). 
These criteria state that three or more of the following criteria 
should be present: abdominal obesity (waist circumference > 102 
cm in men and > 88 cm in women); triglycerides ≥ 150 mg/dl; 
HDL cholesterol < 40 mg/dl in men and < 50 mg/dl in women; 
blood pressure ≥ 130/85 mmHg; and fasting glucose ≥ 110 mg/dl.6
Laboratory analysis
Serum samples were collected between 8:00 AM and 10:00 
AM, after overnight fasting, before the coronary angiography. 
Glucose, total cholesterol, HDL cholesterol, triglyceride and 
albumin levels were measured in the laboratory of Hospital 
Dante Pazzanese de Cardiologia. LDL cholesterol was calculated 
using Friedewald’s formula.7
Blood samples for hormone determinations were taken to the 
Steroid Laboratory of Escola Paulista de Medicina, Universidade 
Federal São Paulo (EPM-Unifesp), immediately after collec-
tion. The samples were centrifuged and frozen at -21 °C for no 
longer than six months. All determinations were performed in 
duplicate. SHBG was measured by means of the immunofluo-
rometric assay (IFMA; Delfia Perkin Elmer, São Paulo, Brazil), 
with a detection limit of 0.5 nmol/l. The intra-assay coefficient 
of variation (CV) was 3.9, 4.9 and 3.3% and the inter-assay CV 
was 2.3, 3.0 and 2.4%, for 25.5, 63.9 and 138.0 nmol/l, respec-
tively. Testosterone was measured by means of radioimmu-
noassay with local historical controls, with a detection limit of 
0.35 nmol/l, intra-assay CV of 7.5 and 13.2% for 16.7 and 3.86 
nmol/l, respectively, and inter-assay CV of 15.5 and 17.6% for 
22.87 and 4.97 nmol/l, respectively. The anti-serum used was 
the anti-testosterone 3-(O-carboxymethyl)-oxime-BSA, and 
the radioactive standard was (1,2,6,73H)-testosterone (250 µCi) 
(Amersham Biosciences, Uppsala, Sweden). E2 was measured by 
means of IFMA (Delfia Perkin Elmer, São Paulo, Brazil), with a 
detection limit of 0.05 nmol/l, intra-assay CV 6.9% and inter-
assay CV 9.7%. Free and bioavailable testosterone were evaluated 
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from serum total testosterone (TT), SHBG and serum albumin in 
accordance with the formula of Vermeulen et al.8
Statistical analysis
Analysis of variance (ANOVA) was used to determine the sta-
tistical significance of numerical variables, and Fisher’s exact 
test was used for categorical variables. Data were analyzed using 
GraphPad Prism 5.0 (San Diego, CA, USA). Relative risk (RR) 
evaluations were used to assess the prevalence of metabolic syn-
drome according to SHBG tercile groups. Statistical significance 
was set at P < 0.05.
RESULTS
A total of 141 patients were eligible for the study. Increased SHBG 
levels were negatively associated with BMI, abdominal circum-
ference and prevalence of diabetes (Table 1). No inverse associa-
tions between SHBG levels and fasting serum triglyceride levels 
(P = 0.06) or between SHBG levels and SAH prevalence (P = 0.08) 
were observed (Table 1). The prevalence of metabolic syndrome 
was significantly higher in the first (lowest) SHBG tercile than in 
the second (middle) and third (highest) SHBG terciles (Table 2). 
A  significant positive association between SHBG and TT lev-
els was observed, but no significant associations were observed 
between SHBG and bioavailable testosterone (BT) or between 
SHBG and free testosterone (FT) (Table 1). Similarly, no statisti-
cally significant association was observed between SHBG and E2 
levels (Table 1).
DISCUSSION
In this sample of 141 male patients admitted to undergo coro-
nary angiography in order to diagnose coronary artery disease, at 
Hospital Dante Pazzanese de Cardiologia, SHBG levels presented 
significant inverse associations with BMI, abdominal circumfer-
ence and prevalence of type 2 diabetes (Table 1). However, no 
inverse associations between SHBG levels and fasting serum tri-
glyceride levels (P = 0.06) or between SHBG levels and SAH prev-
alence (P = 0.08) were observed (Table 1). Furthermore, no sig-
nificant association between the serum levels of SHBG and HDL 
cholesterol was observed (Table 1). A significant negative associ-
ation between SHBG levels and the prevalence of metabolic syn-
drome was found for patients in the second and third SHBG ter-
ciles, with a RR of metabolic syndrome of 0.60 for the second 
tercile (95% CI: 0.06 - 0.47) and 0.29 for the third tercile (95% CI: 
0.16 - 0.54), in comparison with the first tercile (Table 2). 
There is increasing evidence in the literature to suggest that 
low SHBG levels are correlated with components of metabolic 
syndrome. In a recently published paper, Ding et al.9 concluded 
that low SHBG levels are a strong risk predictor for type 2 dia-
betes. Similarly, in a meta-analysis, Ding et al.10 found that white 
males with SHBG levels > 28.3 nmol/l presented a 52% lower 
risk of having diabetes, compared with men with SHBG levels 
≤ 28.3  nmol/l. Colangelo et al.11 observed a significant inverse 
association between SHBG levels and abnormal fasting glucose 
levels and type 2 diabetes among 3,156 men of various ethnici-
ties. Muller et al.12 also reported negative correlations between 
SHBG levels and risk factors for metabolic syndrome. A cross-
sectional study by Gannagé-Yared,13 which included 201 young 
males aged 18-30 years, identified significant negative correla-
tions between serum SHBG levels and the levels of triglycerides, 
HOMA-IR and C-reactive protein (CRP). Finally, in cross-sec-
tional and longitudinal studies on the second and third-genera-
tion populations of the Framingham Heart Study, Bhasin et al.14 
observed that SHBG is an independent predictor for incidence 
of metabolic syndrome. The cross-sectional evaluations in that 
study revealed that TT and FT were associated with the prev-
alence of metabolic syndrome, but a stronger association was 
observed for TT than for FT. Nevertheless, neither TT nor FT 
was associated with the prevalence of metabolic syndrome in the 
longitudinal evaluations. Consequently, these authors concluded 
Table 1. Laboratory and clinical characteristics of patients according to 
their sex hormone-binding globulin (SHBG) terciles 
SHBG tercile
P
1 (lowest) 2 3 (highest)
SHBG mean (nmol/l)
SHBG variation (nmol/l)
27.20 
12.2-35.5
43.11 
36.1-49.9
72.01 
50.5-159
< 0.001
Age (years)* 57.0 56.73 58.88 0.33
BMI (kg/m2)* 28.76 27.46 25.13 < 0.001
Abdominal circumference (cm)* 103.49 97.66 93.53 < 0.001
Diabetes (%) 38.30 21.28 8.51 0.002
Dyslipidemia (%) 70.21 63.83 57.45 0.44
Hypertension (%) 95.74 80.85 87.23 0.08
Blood glucose (mg/dl)* 111.04 107.49 99.07 0.42
Total cholesterol (mg/dl)* 183.72 180.30 168.38 0.22
LDL-cholesterol (mg/dl)* 107.24 105.34 98.70 0.51
HDL-cholesterol (mg/dl)* 40.30 41.98 43.34 0.35
Triglycerides (mg/dl)* 174.38 171.28 131.79 0.06
Total testosterone (nmol/l)* 13.63 16.48 20.84 < 0.001
Bioavailable testosterone (nmol/l)* 7.45 7.23 6.61 0.55
Free testosterone (nmol/l)* 0.32 0.31 0.28 0.50
Estradiol (pmol/l)* 68.72 79.14 74.25 0.29
BMI = body mass index; LDL = low-density lipoprotein; HDL = high density 
lipoprotein. *Data are expressed as means.
Table 2. Prevalence of metabolic syndrome according to sex hormone-
binding globulin (SHBG) terciles
SHBG terciles 1 (lowest) 2 3 (highest)
Metabolic syndrome % 70.21 44.68 19.15
Relative risk 1 0.60 0.29
Confidence interval (95%) 0.06-0.47 0.16-0.54
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that their data did not corroborate the hypothesis that low TT 
levels were independently associated with the prevalence of 
metabolic syndrome. 
The primary abnormality observed in metabolic syndrome 
appears to be insulin resistance in peripheral tissues. Because 
insulin is a potent inhibitor of SHBG production in the liver, it is 
possible that decreased levels of SHBG could be an early marker 
for metabolic syndrome. Similarly, both Heald et al.,15 in a study 
examining European, Pakistani and Afro-Caribbean popula-
tions, and Chubb et al.,16 in a population-based study, suggested 
that SHBG is a potential marker for metabolic syndrome. In a 
recent non-interventional study examining 80 patients with met-
abolic syndrome, it was reported that an increase of one unit in 
insulin levels resulted in a decrease of 0.25 units in SHBG levels.17
Treatment with the PPARγ agonist rosiglitazone has been 
shown to increase the blood levels of SHBG, especially in patients 
with polycystic ovarian syndrome.18
Insulin resistance can be defined as a subnormal state of 
biological responses to circulating insulin. Recent evidence has 
shown that inflammatory serum mediators may induce insu-
lin resistance.19 CRP is the best studied and best characterized 
inflammatory marker. Kupelian et al.,20 in a recent non-interven-
tional population-based study examining 2,301 men aged 30-79 
years, and Gannagé-Yared,13 in a cross-sectional study on young 
men, reported an inverse association between the levels of SHBG 
and CRP, thus corroborating the inverse association between 
SHBG and insulin resistance. 
The current study was not intended to evaluate potential 
causal relationships between SHBG and metabolic syndrome. In 
fact, the existing data in the literature are still insufficient to con-
firm whether SHBG is an early marker or whether it is a compo-
nent of metabolic syndrome.
In this study, a significant positive association between 
SHBG and TT was observed (P < 0.001), but no significant 
associations were observed between SHBG and BT, FT or E2 
(Table  1). In plasma, it is known that only approximately 2% 
of all testosterone circulates in the free form (i.e. the fraction 
known as FT).21 In contrast, 44% is bound to SHBG, and 54% 
binds to albumin.21 Both the FT and the albumin-bound frac-
tions are readily available to tissues. The sum of these two frac-
tions is referred to as the BT level. Therefore, we hypothe-
sized that a significant positive association would be observed 
between TT and SHBG levels.
Epidemiological studies have shown that decreased TT lev-
els are associated with an increased risk of developing metabolic 
syndrome.22,23 These studies have suggested that low testosterone 
levels could contribute towards the physiopathology of meta-
bolic syndrome and that androgen replacement therapy should 
be used for males with metabolic syndrome and testosterone 
deficiency.24,25 However, in a Brazilian study conducted by Callou 
de Sá et al.,5 no significant differences in the prevalence of compo-
nents of metabolic syndrome (as defined according to the NCEP-
ATPIII criteria)6 between TT terciles were observed. Similarly, in 
the study conducted by Bhasin et al.14 examining the second and 
third generations of the Framingham Heart Study, no significant 
associations between the prevalence of metabolic syndrome and 
TT or FT were observed in the longitudinal evaluations. Thus, 
these authors concluded that their data did not corroborate the 
hypothesis that low TT levels were independently associated with 
the prevalence of metabolic syndrome. 
Evaluation of SHBG as a marker for metabolic syndrome among 
males is important because this syndrome consists of a number of 
factors that confer increased risk of cardiovascular diseases, which 
are the main group of diseases causing death in Brazil.
CONCLUSION
We conclude that low serum levels of SHBG were associated 
with higher prevalence of metabolic syndrome in our sample of 
adult Brazilian males aged 40-70 years. Our data should not be 
extrapolated to females or to other ethnic groups or age groups. 
Additional prospective studies to assess this association directly 
are required, especially with regard to the potential causal rela-
tionship between SHBG and metabolic syndrome.
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